• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the...

NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond...

NLA 2025: Practical Strategies for Identifying the Right Patient for Incretin Therapy

by MM360 Staff | Jun 1, 2025 | Myeloma News

Source: Pharmacy Times articles Incretin-based therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, are transforming the management of type 2 diabetes, obesity, and cardiovascular risk. Read More

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

by MM360 Staff | Jun 1, 2025 | Uncategorized

Source: CureToday articles Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck. Read More

Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups

by MM360 Staff | Jun 1, 2025 | Uncategorized

Source: CureToday articles Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT